AxoGen, Inc. (NASDAQ:AXGN – Get Free Report) EVP Marc Began sold 67,500 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $47.34, for a total transaction of $3,195,450.00. Following the completion of the sale, the executive vice president owned 50,135 shares in the company, valued at approximately $2,373,390.90. This trade represents a 57.38% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
AxoGen Stock Performance
Shares of AXGN stock opened at $48.05 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.04 and a current ratio of 6.60. AxoGen, Inc. has a one year low of $13.64 and a one year high of $49.93. The company’s 50-day simple moving average is $43.31 and its 200-day simple moving average is $38.37. The stock has a market capitalization of $2.58 billion, a price-to-earnings ratio of -70.66 and a beta of 1.11.
AxoGen (NASDAQ:AXGN – Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share for the quarter, meeting the consensus estimate of $0.12. AxoGen had a negative return on equity of 8.90% and a negative net margin of 13.36%.The firm had revenue of $69.73 million during the quarter, compared to analyst estimates of $67.10 million. Equities analysts anticipate that AxoGen, Inc. will post -0.45 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Read Our Latest Stock Analysis on AXGN
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AXGN. Commonwealth Equity Services LLC grew its stake in AxoGen by 1.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 21,473 shares of the medical equipment provider’s stock worth $703,000 after buying an additional 371 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in AxoGen by 6.2% in the first quarter. PNC Financial Services Group Inc. now owns 8,943 shares of the medical equipment provider’s stock valued at $296,000 after buying an additional 525 shares during the last quarter. Arax Advisory Partners boosted its holdings in shares of AxoGen by 362.4% during the fourth quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 819 shares during the period. Brooklyn Investment Group boosted its holdings in shares of AxoGen by 4.2% during the fourth quarter. Brooklyn Investment Group now owns 20,568 shares of the medical equipment provider’s stock valued at $688,000 after acquiring an additional 823 shares during the period. Finally, MCF Advisors LLC bought a new position in shares of AxoGen during the fourth quarter worth about $30,000. Institutional investors and hedge funds own 80.29% of the company’s stock.
AxoGen Company Profile
AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.
The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.
Featured Articles
- Five stocks we like better than AxoGen
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.
